November 2, 2026 · Annals of internal medicine · DOI: 10.7326/ANNALS-26-04076-JC

In elective cardiac surgery, perioperative dapagliflozin reduced acute kidney injury vs. placebo at 7 d.

Listen to this summary

This study asks whether perioperative dapagliflozin, an SGLT2 inhibitor, can prevent acute kidney injury (AKI) in patients undergoing elective cardiac surgery. The title reports that dapagliflozin reduced AKI compared with placebo at 7 days. The abstract provided contains no methods or effect sizes, so the sample size, AKI definition, and magnitude of benefit cannot be confirmed from this text.

Matthew T James, Ken Kuljit S Parhar

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play